FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act

The U.S. Food and Drug Administration (FDA) has provided comprehensive guidance on postmarketing safety reporting (PMSR) requirements for combination products. This document, titled Postmarketing Safety Reporting for Combination Products, outlines the necessary steps and regulatory expectations for manufacturers, applicants, and other stakeholders to ensure compliance with FDA regulations.

Scope of the Guidance

Combination products, which integrate drugs, devices, and/or biological products, present unique regulatory challenges. Given their hybrid nature, PMSR obligations for these products must align with multiple sets of regulations, including:

• 21 CFR Part 4 (regulations specific to combination products)
• 21 CFR Part 314 (for drugs)
• 21 CFR Part 600 (for biological products)
• 21 CFR Part 803 (for medical devices)

The guidance helps clarify the regulatory expectations for entities responsible for reporting adverse events related to combination products.

Key PMSR Requirements

To harmonize safety reporting obligations, the FDA mandates that combination product applicants and manufacturers adhere to specific PMSR requirements, including:

1. Individual Case Safety Reports (ICSRs):
   • ICSRs must be submitted in alignment with drug, device, or biologic reporting requirements, depending on the primary mode of action (PMOA) of the combination product.
   • Serious, unexpected adverse drug experiences must be reported within 15 calendar days.
2. Five-Day and Malfunction Reports:
   • Device-related adverse events meeting the criteria for a five-day report must be submitted to the FDA within the required timeframe.
   • Malfunction reports for device-led combination products should align with 21 CFR Part 803.
3. Periodic Safety Reports:
   • Periodic adverse drug experience reports (PADERs) and periodic benefit-risk evaluation reports (PBRERs) must be submitted for combination products containing drugs.
4. Recordkeeping and Submission Requirements:
   • Manufacturers must maintain records of reported adverse events and ensure compliance with electronic submission guidelines.

Compliance Timelines and Industry Responsibilities

The FDA has provided a phased approach to compliance, allowing time for industry stakeholders to implement necessary processes. Failure to adhere to PMSR requirements could lead to regulatory actions, including warning letters, fines, or product recalls.

Conclusion

The FDA’s guidance on PMSR for combination products is essential for ensuring patient safety and regulatory compliance. Manufacturers must understand and implement these requirements to align with FDA expectations and maintain the integrity of their postmarketing surveillance programs. By doing so, they can enhance product safety while avoiding regulatory pitfalls.

FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act – by Shudarsana Company